A Case of Therapy-related ALL with MLL Gene Rearrangement Following Treatment of Breast Cancer
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
ALL with MLL gene rearrangement secondary to chemotherapy has been rarely reported. We report a case of therapy-related ALL (t-ALL) with MLL gene rearrangement in a patient who had undergone treatment for breast cancer. A 60-yr-old woman with breast cancer underwent breastconserving surgery followed by 6 cycles of adjuvant chemotherapy (cyclophosphamide, epirubicin, and fluorouracil) and radiation therapy (dose, 5,040 cGy to the left breast and a 1,000 cGy boost to the tumor bed). A follow-up examination performed 14 months after the chemotherapy revealed no evidence of breast malignancy. However, the patient’s complete blood cell count indicated acute leukemia: white blood cell count, 174.1×109/L with 88% blasts; Hb level, 12.5 g/dL; and platelet count, 103.0×109/L. Examination of the bone marrow aspirate smear revealed a high percentage of blasts (85.1% of all nucleated cells); the blasts showed a pro-B immunophenotype and were positive for CD19, CD79a, HLA-DR, CD34, and terminal deoxynucleotidyl transferase (TdT). Cytogenetic and FISH analyses revealed t(4;11)(q21;q23) and MLL gene rearrangement, respectively. The patient received induction chemotherapy with cyclophosphamide, vincristine, doxorubicin, and dexamethasone and achieved complete remission. Following consolidation chemotherapy, she underwent allogenic peripheral blood stem cell transplantation and has been clinically stable. To our knowledge, this is the first reported case of t-ALL with MLL gene rearrangement following treatment of breast cancer in Korea. (Korean J Lab Med 2010;30:255-9)
Abstract
ALL with MLL gene rearrangement secondary to chemotherapy has been rarely reported. We report a case of therapy-related ALL (t-ALL) with MLL gene rearrangement in a patient who had undergone treatment for breast cancer. A 60-yr-old woman with breast cancer underwent breastconserving surgery followed by 6 cycles of adjuvant chemotherapy (cyclophosphamide, epirubicin, and fluorouracil) and radiation therapy (dose, 5,040 cGy to the left breast and a 1,000 cGy boost to the tumor bed). A follow-up examination performed 14 months after the chemotherapy revealed no evidence of breast malignancy. However, the patient’s complete blood cell count indicated acute leukemia: white blood cell count, 174.1×109/L with 88% blasts; Hb level, 12.5 g/dL; and platelet count, 103.0×109/L. Examination of the bone marrow aspirate smear revealed a high percentage of blasts (85.1% of all nucleated cells); the blasts showed a pro-B immunophenotype and were positive for CD19, CD79a, HLA-DR, CD34, and terminal deoxynucleotidyl transferase (TdT). Cytogenetic and FISH analyses revealed t(4;11)(q21;q23) and MLL gene rearrangement, respectively. The patient received induction chemotherapy with cyclophosphamide, vincristine, doxorubicin, and dexamethasone and achieved complete remission. Following consolidation chemotherapy, she underwent allogenic peripheral blood stem cell transplantation and has been clinically stable. To our knowledge, this is the first reported case of t-ALL with MLL gene rearrangement following treatment of breast cancer in Korea. (Korean J Lab Med 2010;30:255-9)
참고문헌 (18)
- Leone G, "The incidence of secondary leukemias", Haematologica, 84, pp.937~945 (1999)
- Pedersen-Bjergaard J, "Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and AML", Blood, 99, pp.1909~1912 (2002)
- Pagano L, "Clinical and epidemiological features of ALL following a previous malignancy", Leuk Lymphoma, 39, pp.465~475 (2000)
- Andersen MK, "Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992", Br J Haematol, 114, pp.539~543 (2001)
- Pagano L, "Acute lymphoblastic leukaemia occurring as second malignancy:report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto", Br J Haematol, 106, pp.1037~1040 (1999)
- Song SH, "Therapyrelated acute myelogenous leukemia with complex chromosomal defect", Korean J Hematol, 27, pp.117~122 (1992)
- r M, "Four cases of therapy-related leukemia", J Korean Med Sci, 14, pp.327~329 (1999)
- Kim M, "A case of therapy-related AML associated with inv(16), with subsequent development of t(9;22)", Leukemia, 20, pp.746~748 (2006)
- 이소영, "Inv(16)을 동반한 치료 관련성 급성골수성백혈병 1예", The Korean Journal of Laboratory Medicine, 27(1), pp.19~21 (2007), 대한진단검사의학회
- Lee SG, "Therapy-related ALL with t(9;22)(q34;q11.2):a case study and review of the literature", Cancer Genet Cytogenet, 191, pp.51~54 (2009)
- Smith SM, "Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series", Blood, 102, pp.43~52 (2003)
- Secker-Walker LM, "Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop", Leukemia, 12, pp.840~844 (1998)
- Ishizawa S, "High frequency of pro-B ALL in adults with secondary leukemia with 11q23 abnormalities", Leukemia, 17, pp.1091~1095 (2003)
- Tsujioka T, "MLL", AF-1p fusion in therapy-related early pre-B ALL with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia, 2003, pp.78, 439~442
- Millot F, "Therapy-related ALL with MLL rearrangement following treatment of Burkitt's leukemia", Leuk Lymphoma, 46, pp.925~927 (2005)
- Hrusak O, "Antigen expression patterns reflecting genotype of acute leukemias", Leukemia, 16, pp.1233~1258 (2002)
- Schoch C, "Karyotype is an independent prognostic parameter in therapy-related AML (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML", Leukemia, 18, pp.120~125 (2004)
- Pagano L, "Acute leukemia following a previous malignancy: do acute lymphoid leukemia and AML have common risk factors?", Hematol J, 1, pp.329~332 (2000)